Crisscross CTL Induction by SYT-SSX Junction Peptide and Its HLA-A*2402 Anchor Substitute
Kazunori Ida(Asahi University), Noriyuki Sato(Sapporo Higashi Tokushukai Hospital), Akira Myoui(Osaka University Hospital), Hiroeki Sahara(Sapporo Medical University), Akira Kawai(GTx (United States)), Yuki Nabeta(Sapporo Medical University), Hiroaki Hiraga, Seiichi Matsumoto, Satoshi Nagoya(Sapporo Medical University), Satoshi Kawaguchi(Sapporo Medical University), Toshihiko Torigoe(Sapporo Medical University), Shingo Ichimiya(Sapporo Medical University), Toshihiko Yamashita(Sapporo Medical University), Kenjiro Kamiguchi(Sapporo Medical University), Hideyuki Ikeda(Sapporo Medical University), Hideki Yoshikawa(Osaka University), Nobuhito Araki(Mie University), Takuro Wada(Sapporo Medical University), Yuriko Sato(Sapporo Medical University), Tomohide Tsukahara(Sapporo Medical University), Takeshi Ishii(Chiba Cancer Center), Toshifumi Ozaki(Okayama University)
Cited by 32
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803